Evaluation of benefit-risk

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Drug authorization, prescription and utilization are all based on benefit-risk assessment. This is made difficult by the apparent lack of objective means to measure the balance and by limitations regarding each of the two items. Benefit is sometimes measured by surrogate indicators of a real clinical advantage. It is assumed to be applicable to individuals even though it is measured in populations, and is represented in different ways that may convey different messages to physicians and patients. Risks are also hard to predict on an individual level. They may also be overlooked or revealed later than benefit, thus biasing the balance for a long time. Their causal relationship with the treatment is often not fully established. The benefit-risk balance itself has no generally recognized measure. This is why benefits and risks are hard to compare; either one or both may occur in single patients, and a risk-benefit profile that is acceptable in severe diseases may not be acceptable in diseases with a favourable prognosis.Pharmacoeconomics offers promising methods of health outcomes modelling using QALYs that take into consideration quality of life as well as survival. Primarily conceived as a guide for establishing the value of a treatment, they may prove useful as a means of trading efficacy and safety. However, quality of life is not always or adequately assessed in clinical studies. It is also not clear which is the most appropriate model to calculate QALYs for clinical purposes and how it can be used as a predictive tool at the individual level.

Original languageEnglish
Pages (from-to)981-986
Number of pages6
JournalPharmacoEconomics
Volume28
Issue number11
DOIs
Publication statusPublished - 2010

Fingerprint

Quality-Adjusted Life Years
Quality of Life
Drug Utilization
Drug Prescriptions
Pharmaceutical Economics
Physicians
Safety
Survival
Health
Therapeutics
Population
Clinical Studies

Keywords

  • benefit-risk-assessment
  • quality-adjusted-life-years

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Evaluation of benefit-risk. / Garattini, Silvio.

In: PharmacoEconomics, Vol. 28, No. 11, 2010, p. 981-986.

Research output: Contribution to journalArticle

Garattini, Silvio. / Evaluation of benefit-risk. In: PharmacoEconomics. 2010 ; Vol. 28, No. 11. pp. 981-986.
@article{62d0422e42da404db628fc1f82e8a03a,
title = "Evaluation of benefit-risk",
abstract = "Drug authorization, prescription and utilization are all based on benefit-risk assessment. This is made difficult by the apparent lack of objective means to measure the balance and by limitations regarding each of the two items. Benefit is sometimes measured by surrogate indicators of a real clinical advantage. It is assumed to be applicable to individuals even though it is measured in populations, and is represented in different ways that may convey different messages to physicians and patients. Risks are also hard to predict on an individual level. They may also be overlooked or revealed later than benefit, thus biasing the balance for a long time. Their causal relationship with the treatment is often not fully established. The benefit-risk balance itself has no generally recognized measure. This is why benefits and risks are hard to compare; either one or both may occur in single patients, and a risk-benefit profile that is acceptable in severe diseases may not be acceptable in diseases with a favourable prognosis.Pharmacoeconomics offers promising methods of health outcomes modelling using QALYs that take into consideration quality of life as well as survival. Primarily conceived as a guide for establishing the value of a treatment, they may prove useful as a means of trading efficacy and safety. However, quality of life is not always or adequately assessed in clinical studies. It is also not clear which is the most appropriate model to calculate QALYs for clinical purposes and how it can be used as a predictive tool at the individual level.",
keywords = "benefit-risk-assessment, quality-adjusted-life-years",
author = "Silvio Garattini",
year = "2010",
doi = "10.2165/11537590-000000000-00000",
language = "English",
volume = "28",
pages = "981--986",
journal = "PharmacoEconomics",
issn = "1170-7690",
publisher = "Adis International Ltd",
number = "11",

}

TY - JOUR

T1 - Evaluation of benefit-risk

AU - Garattini, Silvio

PY - 2010

Y1 - 2010

N2 - Drug authorization, prescription and utilization are all based on benefit-risk assessment. This is made difficult by the apparent lack of objective means to measure the balance and by limitations regarding each of the two items. Benefit is sometimes measured by surrogate indicators of a real clinical advantage. It is assumed to be applicable to individuals even though it is measured in populations, and is represented in different ways that may convey different messages to physicians and patients. Risks are also hard to predict on an individual level. They may also be overlooked or revealed later than benefit, thus biasing the balance for a long time. Their causal relationship with the treatment is often not fully established. The benefit-risk balance itself has no generally recognized measure. This is why benefits and risks are hard to compare; either one or both may occur in single patients, and a risk-benefit profile that is acceptable in severe diseases may not be acceptable in diseases with a favourable prognosis.Pharmacoeconomics offers promising methods of health outcomes modelling using QALYs that take into consideration quality of life as well as survival. Primarily conceived as a guide for establishing the value of a treatment, they may prove useful as a means of trading efficacy and safety. However, quality of life is not always or adequately assessed in clinical studies. It is also not clear which is the most appropriate model to calculate QALYs for clinical purposes and how it can be used as a predictive tool at the individual level.

AB - Drug authorization, prescription and utilization are all based on benefit-risk assessment. This is made difficult by the apparent lack of objective means to measure the balance and by limitations regarding each of the two items. Benefit is sometimes measured by surrogate indicators of a real clinical advantage. It is assumed to be applicable to individuals even though it is measured in populations, and is represented in different ways that may convey different messages to physicians and patients. Risks are also hard to predict on an individual level. They may also be overlooked or revealed later than benefit, thus biasing the balance for a long time. Their causal relationship with the treatment is often not fully established. The benefit-risk balance itself has no generally recognized measure. This is why benefits and risks are hard to compare; either one or both may occur in single patients, and a risk-benefit profile that is acceptable in severe diseases may not be acceptable in diseases with a favourable prognosis.Pharmacoeconomics offers promising methods of health outcomes modelling using QALYs that take into consideration quality of life as well as survival. Primarily conceived as a guide for establishing the value of a treatment, they may prove useful as a means of trading efficacy and safety. However, quality of life is not always or adequately assessed in clinical studies. It is also not clear which is the most appropriate model to calculate QALYs for clinical purposes and how it can be used as a predictive tool at the individual level.

KW - benefit-risk-assessment

KW - quality-adjusted-life-years

UR - http://www.scopus.com/inward/record.url?scp=77958008305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958008305&partnerID=8YFLogxK

U2 - 10.2165/11537590-000000000-00000

DO - 10.2165/11537590-000000000-00000

M3 - Article

C2 - 20681742

AN - SCOPUS:77958008305

VL - 28

SP - 981

EP - 986

JO - PharmacoEconomics

JF - PharmacoEconomics

SN - 1170-7690

IS - 11

ER -